| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 62 | 2024 | 1429 | 7.590 |
Why?
|
| Immunoconjugates | 20 | 2023 | 279 | 3.410 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 12 | 2023 | 181 | 2.770 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 73 | 2023 | 15862 | 2.420 |
Why?
|
| Ki-1 Antigen | 9 | 2022 | 182 | 2.180 |
Why?
|
| Lymphoma | 14 | 2019 | 1467 | 1.940 |
Why?
|
| Pregnancy Complications, Neoplastic | 4 | 2017 | 222 | 1.760 |
Why?
|
| Lymphoma, Non-Hodgkin | 11 | 2019 | 1039 | 1.580 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 9 | 2022 | 387 | 1.290 |
Why?
|
| Rituximab | 26 | 2022 | 1528 | 1.250 |
Why?
|
| Doxorubicin | 35 | 2023 | 3005 | 1.090 |
Why?
|
| Lymphoma, T-Cell | 6 | 2019 | 361 | 0.970 |
Why?
|
| Mediastinal Neoplasms | 5 | 2019 | 423 | 0.870 |
Why?
|
| Cyclophosphamide | 22 | 2023 | 3001 | 0.850 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 12 | 2022 | 1664 | 0.850 |
Why?
|
| Prednisone | 15 | 2023 | 984 | 0.830 |
Why?
|
| Vincristine | 17 | 2022 | 1511 | 0.800 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 11 | 2017 | 864 | 0.780 |
Why?
|
| Young Adult | 59 | 2024 | 21445 | 0.770 |
Why?
|
| Adult | 100 | 2024 | 77950 | 0.760 |
Why?
|
| Lymphocytes | 2 | 2017 | 1234 | 0.740 |
Why?
|
| Vinblastine | 18 | 2023 | 453 | 0.700 |
Why?
|
| Leukocyte Count | 2 | 2017 | 684 | 0.690 |
Why?
|
| Neoplasm Staging | 34 | 2023 | 13658 | 0.690 |
Why?
|
| Bleomycin | 16 | 2023 | 467 | 0.680 |
Why?
|
| Treatment Outcome | 52 | 2021 | 32848 | 0.670 |
Why?
|
| Everolimus | 2 | 2020 | 415 | 0.670 |
Why?
|
| Sirolimus | 3 | 2020 | 814 | 0.660 |
Why?
|
| Recurrence | 27 | 2020 | 4758 | 0.660 |
Why?
|
| Histone Deacetylases | 1 | 2020 | 365 | 0.640 |
Why?
|
| Etoposide | 12 | 2020 | 870 | 0.640 |
Why?
|
| Middle Aged | 95 | 2023 | 86204 | 0.630 |
Why?
|
| Lymphoma, B-Cell | 8 | 2018 | 895 | 0.610 |
Why?
|
| Humans | 143 | 2024 | 261506 | 0.600 |
Why?
|
| Aged | 81 | 2022 | 70117 | 0.600 |
Why?
|
| Salvage Therapy | 14 | 2018 | 2054 | 0.600 |
Why?
|
| Antineoplastic Agents | 15 | 2021 | 14289 | 0.590 |
Why?
|
| Disease-Free Survival | 28 | 2019 | 10001 | 0.580 |
Why?
|
| Platelet Count | 1 | 2017 | 490 | 0.570 |
Why?
|
| Female | 100 | 2023 | 141928 | 0.560 |
Why?
|
| Male | 95 | 2023 | 123000 | 0.560 |
Why?
|
| Neutrophils | 2 | 2017 | 835 | 0.560 |
Why?
|
| Dacarbazine | 16 | 2023 | 485 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 16 | 2022 | 10035 | 0.520 |
Why?
|
| Abortion, Spontaneous | 1 | 2016 | 112 | 0.520 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2020 | 1546 | 0.510 |
Why?
|
| Lymphoma, Follicular | 6 | 2020 | 587 | 0.500 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 4 | 2019 | 301 | 0.490 |
Why?
|
| Aged, 80 and over | 38 | 2020 | 29902 | 0.490 |
Why?
|
| Kaplan-Meier Estimate | 19 | 2018 | 6207 | 0.480 |
Why?
|
| Congenital Abnormalities | 1 | 2016 | 260 | 0.460 |
Why?
|
| Radiotherapy | 4 | 2017 | 1824 | 0.460 |
Why?
|
| Adolescent | 42 | 2024 | 31252 | 0.460 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 16 | 2022 | 6550 | 0.450 |
Why?
|
| CD40 Antigens | 1 | 2013 | 104 | 0.450 |
Why?
|
| B-Lymphocytes | 4 | 2019 | 1294 | 0.450 |
Why?
|
| Blood Platelets | 1 | 2017 | 731 | 0.440 |
Why?
|
| Survival Rate | 20 | 2020 | 12221 | 0.440 |
Why?
|
| Stem Cell Transplantation | 8 | 2020 | 1360 | 0.440 |
Why?
|
| Positron-Emission Tomography | 12 | 2023 | 2173 | 0.430 |
Why?
|
| Positron Emission Tomography Computed Tomography | 6 | 2023 | 833 | 0.410 |
Why?
|
| Radiotherapy, Intensity-Modulated | 6 | 2018 | 2104 | 0.400 |
Why?
|
| Immunophenotyping | 1 | 2016 | 1681 | 0.400 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2019 | 3251 | 0.390 |
Why?
|
| Histone Deacetylase Inhibitors | 5 | 2020 | 612 | 0.380 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2018 | 713 | 0.370 |
Why?
|
| Combined Modality Therapy | 15 | 2017 | 8865 | 0.370 |
Why?
|
| Drug Administration Schedule | 14 | 2021 | 3472 | 0.370 |
Why?
|
| Follow-Up Studies | 23 | 2021 | 14889 | 0.360 |
Why?
|
| Gene Expression | 1 | 2018 | 3570 | 0.350 |
Why?
|
| Antibodies, Monoclonal | 7 | 2020 | 4367 | 0.340 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2018 | 502 | 0.330 |
Why?
|
| Antineoplastic Agents, Immunological | 6 | 2020 | 1249 | 0.320 |
Why?
|
| Retrospective Studies | 28 | 2023 | 37905 | 0.310 |
Why?
|
| Prognosis | 18 | 2020 | 21713 | 0.300 |
Why?
|
| Survival Analysis | 14 | 2023 | 9180 | 0.300 |
Why?
|
| Clinical Decision-Making | 2 | 2023 | 524 | 0.290 |
Why?
|
| Breast Implants | 3 | 2017 | 391 | 0.280 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 184 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2020 | 4938 | 0.280 |
Why?
|
| Ifosfamide | 3 | 2018 | 344 | 0.280 |
Why?
|
| Antigens, Surface | 1 | 2007 | 295 | 0.280 |
Why?
|
| Oligopeptides | 2 | 2021 | 429 | 0.260 |
Why?
|
| Hydroxamic Acids | 4 | 2016 | 442 | 0.260 |
Why?
|
| Physicians | 2 | 2023 | 882 | 0.250 |
Why?
|
| Bortezomib | 3 | 2018 | 543 | 0.250 |
Why?
|
| Radiopharmaceuticals | 4 | 2017 | 1301 | 0.250 |
Why?
|
| Carboplatin | 3 | 2018 | 823 | 0.240 |
Why?
|
| Hematologic Neoplasms | 2 | 2014 | 1870 | 0.240 |
Why?
|
| Retreatment | 4 | 2018 | 452 | 0.240 |
Why?
|
| Radiation Pneumonitis | 2 | 2016 | 301 | 0.240 |
Why?
|
| Tumor Burden | 3 | 2019 | 1987 | 0.230 |
Why?
|
| Melphalan | 5 | 2018 | 834 | 0.220 |
Why?
|
| Disease Management | 3 | 2017 | 1052 | 0.220 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 4988 | 0.210 |
Why?
|
| Transplantation, Autologous | 9 | 2018 | 1914 | 0.210 |
Why?
|
| Radioimmunotherapy | 2 | 2020 | 119 | 0.210 |
Why?
|
| Hematologic Diseases | 4 | 2015 | 242 | 0.210 |
Why?
|
| Pregnancy | 4 | 2017 | 7573 | 0.200 |
Why?
|
| Depsipeptides | 2 | 2019 | 78 | 0.200 |
Why?
|
| Algorithms | 1 | 2013 | 3890 | 0.200 |
Why?
|
| Transplantation Conditioning | 3 | 2016 | 2238 | 0.200 |
Why?
|
| Remission Induction | 9 | 2018 | 3569 | 0.190 |
Why?
|
| Oncologists | 1 | 2023 | 134 | 0.190 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2017 | 1226 | 0.190 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2023 | 294 | 0.180 |
Why?
|
| Mycosis Fungoides | 1 | 2023 | 320 | 0.180 |
Why?
|
| Deoxycytidine | 5 | 2018 | 1353 | 0.180 |
Why?
|
| Radiation Injuries | 3 | 2016 | 1411 | 0.180 |
Why?
|
| Models, Economic | 1 | 2020 | 101 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2020 | 598 | 0.180 |
Why?
|
| beta 2-Microglobulin | 2 | 2018 | 184 | 0.170 |
Why?
|
| Maximum Tolerated Dose | 5 | 2016 | 1290 | 0.170 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 3719 | 0.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 1048 | 0.170 |
Why?
|
| Mitoxantrone | 2 | 2017 | 216 | 0.170 |
Why?
|
| Piperidines | 2 | 2022 | 1035 | 0.170 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2005 | 1216 | 0.160 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2018 | 31 | 0.160 |
Why?
|
| Cohort Studies | 8 | 2018 | 9244 | 0.160 |
Why?
|
| Diagnostic Imaging | 2 | 2017 | 1162 | 0.160 |
Why?
|
| Methotrexate | 5 | 2023 | 999 | 0.150 |
Why?
|
| Caregivers | 1 | 2023 | 677 | 0.150 |
Why?
|
| Burkitt Lymphoma | 1 | 2020 | 335 | 0.150 |
Why?
|
| Chemoradiotherapy | 5 | 2018 | 1946 | 0.150 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2018 | 182 | 0.150 |
Why?
|
| Disease Progression | 9 | 2019 | 6682 | 0.150 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2016 | 30 | 0.150 |
Why?
|
| Orbital Neoplasms | 1 | 2019 | 224 | 0.150 |
Why?
|
| Neoplasms, Second Primary | 2 | 2023 | 1350 | 0.150 |
Why?
|
| Drug Resistance | 1 | 2018 | 587 | 0.140 |
Why?
|
| Vidarabine | 3 | 2017 | 1341 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2018 | 204 | 0.140 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 124 | 0.140 |
Why?
|
| Nausea | 2 | 2016 | 525 | 0.140 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2015 | 24 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 945 | 0.130 |
Why?
|
| Chemokine CCL4 | 1 | 2015 | 63 | 0.130 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2015 | 37 | 0.130 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2015 | 107 | 0.130 |
Why?
|
| Chemokine CCL3 | 1 | 2015 | 63 | 0.130 |
Why?
|
| Abortion, Induced | 1 | 2016 | 91 | 0.130 |
Why?
|
| Interferons | 1 | 2017 | 291 | 0.130 |
Why?
|
| Splenic Neoplasms | 1 | 2016 | 119 | 0.130 |
Why?
|
| Bile Ducts | 1 | 2016 | 113 | 0.130 |
Why?
|
| Breast Neoplasms | 7 | 2018 | 15694 | 0.130 |
Why?
|
| Troponin I | 1 | 2016 | 127 | 0.130 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2018 | 406 | 0.130 |
Why?
|
| Organs at Risk | 1 | 2018 | 514 | 0.130 |
Why?
|
| Postpartum Period | 1 | 2016 | 259 | 0.130 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 783 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2018 | 649 | 0.130 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 4557 | 0.120 |
Why?
|
| Lung | 2 | 2016 | 3151 | 0.120 |
Why?
|
| United States | 10 | 2023 | 15433 | 0.120 |
Why?
|
| Eye Neoplasms | 1 | 2017 | 247 | 0.120 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2015 | 146 | 0.120 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2015 | 205 | 0.120 |
Why?
|
| Anthracyclines | 1 | 2016 | 331 | 0.120 |
Why?
|
| Dexamethasone | 5 | 2018 | 1450 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 810 | 0.120 |
Why?
|
| Pyrimidines | 4 | 2019 | 3518 | 0.120 |
Why?
|
| Thalidomide | 2 | 2014 | 569 | 0.120 |
Why?
|
| Cholestasis | 1 | 2016 | 203 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 196 | 0.120 |
Why?
|
| Meningeal Neoplasms | 1 | 2018 | 441 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 799 | 0.120 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 643 | 0.120 |
Why?
|
| Fatigue | 3 | 2014 | 1239 | 0.120 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2016 | 343 | 0.110 |
Why?
|
| Communicable Diseases | 1 | 2015 | 193 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2016 | 726 | 0.110 |
Why?
|
| Vomiting | 1 | 2014 | 354 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2018 | 5178 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2018 | 6869 | 0.110 |
Why?
|
| Time Factors | 5 | 2018 | 12926 | 0.110 |
Why?
|
| Antigens, CD20 | 1 | 2013 | 206 | 0.110 |
Why?
|
| Maytansine | 1 | 2012 | 38 | 0.110 |
Why?
|
| Monocytes | 1 | 2016 | 788 | 0.110 |
Why?
|
| Bone Resorption | 1 | 2012 | 138 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 2330 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4298 | 0.100 |
Why?
|
| Immunotoxins | 1 | 2012 | 117 | 0.100 |
Why?
|
| Bridged-Ring Compounds | 1 | 2012 | 183 | 0.100 |
Why?
|
| Lactams, Macrocyclic | 1 | 2012 | 90 | 0.100 |
Why?
|
| Quality of Life | 3 | 2023 | 4532 | 0.100 |
Why?
|
| Benzoquinones | 1 | 2012 | 108 | 0.100 |
Why?
|
| Spinal Cord | 1 | 2015 | 690 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2019 | 2218 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 1248 | 0.100 |
Why?
|
| Heart | 1 | 2018 | 1223 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 1022 | 0.100 |
Why?
|
| Bone Density Conservation Agents | 1 | 2012 | 198 | 0.100 |
Why?
|
| Indoles | 2 | 2013 | 1009 | 0.100 |
Why?
|
| Diphosphonates | 1 | 2012 | 262 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2012 | 196 | 0.090 |
Why?
|
| Treatment Failure | 3 | 2018 | 1391 | 0.090 |
Why?
|
| Cytarabine | 4 | 2018 | 1973 | 0.090 |
Why?
|
| Tissue Distribution | 1 | 2011 | 875 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2016 | 732 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2016 | 1863 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2015 | 2054 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2016 | 806 | 0.090 |
Why?
|
| Skin Neoplasms | 2 | 2023 | 4654 | 0.090 |
Why?
|
| Models, Biological | 1 | 2018 | 3254 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2011 | 362 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 1399 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2015 | 4757 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 1763 | 0.080 |
Why?
|
| Child | 6 | 2016 | 29154 | 0.080 |
Why?
|
| Janus Kinase 2 | 1 | 2012 | 679 | 0.080 |
Why?
|
| Pyrazines | 1 | 2011 | 495 | 0.080 |
Why?
|
| Busulfan | 3 | 2018 | 764 | 0.080 |
Why?
|
| Pyrroles | 1 | 2012 | 576 | 0.080 |
Why?
|
| Age Factors | 2 | 2014 | 5377 | 0.080 |
Why?
|
| Genomics | 1 | 2018 | 2738 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 7551 | 0.070 |
Why?
|
| Pentostatin | 2 | 2019 | 119 | 0.070 |
Why?
|
| Imidazoles | 1 | 2012 | 999 | 0.070 |
Why?
|
| Incidence | 4 | 2018 | 5673 | 0.070 |
Why?
|
| Yttrium Radioisotopes | 2 | 2020 | 178 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 2390 | 0.070 |
Why?
|
| Neoplasms | 3 | 2017 | 15193 | 0.070 |
Why?
|
| Autografts | 2 | 2018 | 165 | 0.070 |
Why?
|
| Bone Marrow Diseases | 2 | 2019 | 177 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 5159 | 0.070 |
Why?
|
| Benzamides | 1 | 2011 | 1832 | 0.070 |
Why?
|
| Trastuzumab | 2 | 2005 | 696 | 0.070 |
Why?
|
| Neutropenia | 3 | 2017 | 968 | 0.070 |
Why?
|
| Drugs, Investigational | 1 | 2007 | 135 | 0.070 |
Why?
|
| Mediastinum | 2 | 2019 | 268 | 0.070 |
Why?
|
| Biopsy | 3 | 2019 | 3443 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 1493 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 7702 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2012 | 1506 | 0.070 |
Why?
|
| Lung Diseases | 3 | 2017 | 717 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2012 | 2488 | 0.060 |
Why?
|
| Glycolysis | 2 | 2019 | 519 | 0.060 |
Why?
|
| North America | 2 | 2018 | 314 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 3869 | 0.060 |
Why?
|
| Drug Design | 1 | 2007 | 375 | 0.060 |
Why?
|
| Radiotherapy Dosage | 3 | 2017 | 3842 | 0.060 |
Why?
|
| Holistic Nursing | 1 | 2003 | 1 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 4314 | 0.060 |
Why?
|
| Education, Nursing, Continuing | 1 | 2003 | 25 | 0.060 |
Why?
|
| Risk Factors | 5 | 2020 | 17523 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3230 | 0.060 |
Why?
|
| Indians, North American | 1 | 2003 | 87 | 0.060 |
Why?
|
| Inservice Training | 1 | 2003 | 78 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 5687 | 0.060 |
Why?
|
| Radiometry | 2 | 2019 | 980 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 669 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2016 | 1546 | 0.050 |
Why?
|
| Interleukins | 1 | 2004 | 325 | 0.050 |
Why?
|
| Liver | 2 | 2016 | 2961 | 0.050 |
Why?
|
| Patient Preference | 1 | 2024 | 218 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2016 | 2307 | 0.050 |
Why?
|
| Polyethylene Glycols | 2 | 2015 | 615 | 0.050 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2017 | 393 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 2231 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 4849 | 0.050 |
Why?
|
| Risk | 2 | 2016 | 1972 | 0.050 |
Why?
|
| Biomarkers | 3 | 2016 | 5047 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 1533 | 0.050 |
Why?
|
| Propensity Score | 1 | 2023 | 750 | 0.050 |
Why?
|
| Anemia | 2 | 2017 | 689 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2013 | 1382 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 1742 | 0.050 |
Why?
|
| Prevalence | 2 | 2019 | 3260 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 1547 | 0.040 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 10331 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 4892 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 226 | 0.040 |
Why?
|
| Bone Marrow | 2 | 2017 | 2358 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 2 | 2015 | 589 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 130 | 0.040 |
Why?
|
| Comorbidity | 2 | 2016 | 2352 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2012 | 3341 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 3981 | 0.040 |
Why?
|
| Azepines | 1 | 2019 | 124 | 0.040 |
Why?
|
| Reed-Sternberg Cells | 1 | 2018 | 44 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2012 | 1544 | 0.040 |
Why?
|
| Carmustine | 1 | 2018 | 214 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2016 | 2843 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 700 | 0.040 |
Why?
|
| Aminopterin | 1 | 2016 | 30 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2016 | 31 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2018 | 272 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2018 | 290 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2018 | 12873 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2004 | 1616 | 0.040 |
Why?
|
| Procarbazine | 1 | 2016 | 69 | 0.040 |
Why?
|
| Therapeutics | 1 | 2016 | 34 | 0.040 |
Why?
|
| Hepatomegaly | 1 | 2016 | 69 | 0.040 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2018 | 2370 | 0.030 |
Why?
|
| Europe | 1 | 2018 | 649 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 5112 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 176 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2005 | 4844 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 202 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2016 | 153 | 0.030 |
Why?
|
| Isochromosomes | 1 | 2016 | 55 | 0.030 |
Why?
|
| Orbit | 1 | 2017 | 205 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 173 | 0.030 |
Why?
|
| Splenomegaly | 1 | 2016 | 158 | 0.030 |
Why?
|
| Aurora Kinase A | 1 | 2016 | 202 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2017 | 553 | 0.030 |
Why?
|
| Health Status | 1 | 2019 | 590 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2016 | 166 | 0.030 |
Why?
|
| Czech Republic | 1 | 2015 | 14 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2017 | 726 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2016 | 174 | 0.030 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2015 | 32 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2016 | 233 | 0.030 |
Why?
|
| Exanthema | 1 | 2017 | 211 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2015 | 47 | 0.030 |
Why?
|
| New Zealand | 1 | 2015 | 60 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 552 | 0.030 |
Why?
|
| Poland | 1 | 2015 | 61 | 0.030 |
Why?
|
| Genes, Immunoglobulin | 1 | 2015 | 87 | 0.030 |
Why?
|
| France | 1 | 2015 | 108 | 0.030 |
Why?
|
| Trisomy | 1 | 2016 | 231 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2016 | 234 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 254 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 383 | 0.030 |
Why?
|
| Cardiotoxicity | 1 | 2016 | 155 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2016 | 756 | 0.030 |
Why?
|
| Mass Screening | 1 | 2003 | 1509 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2016 | 317 | 0.030 |
Why?
|
| Bilirubin | 1 | 2016 | 221 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2015 | 193 | 0.030 |
Why?
|
| SEER Program | 1 | 2018 | 1000 | 0.030 |
Why?
|
| Spasm | 1 | 2014 | 59 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 236 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 225 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 2518 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2014 | 87 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2014 | 125 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2016 | 329 | 0.030 |
Why?
|
| Genes, bcl-2 | 1 | 2014 | 166 | 0.030 |
Why?
|
| Headache | 1 | 2014 | 163 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 2018 | 529 | 0.030 |
Why?
|
| Topotecan | 1 | 2014 | 239 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 657 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 2013 | 73 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2017 | 550 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2015 | 256 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2017 | 710 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2016 | 349 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2016 | 749 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 2588 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 650 | 0.030 |
Why?
|
| Consensus | 1 | 2016 | 978 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 661 | 0.030 |
Why?
|
| Genes, myc | 1 | 2014 | 358 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 1351 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2015 | 333 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2003 | 1833 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 631 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 1489 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1945 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 846 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 709 | 0.030 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 14551 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2012 | 159 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 1656 | 0.020 |
Why?
|
| Alopecia | 1 | 2012 | 126 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2012 | 219 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 2232 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2015 | 492 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 2292 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 966 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 1390 | 0.020 |
Why?
|
| Apoptosis | 1 | 2004 | 7591 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 500 | 0.020 |
Why?
|
| Azacitidine | 1 | 2016 | 1149 | 0.020 |
Why?
|
| Bone Density | 1 | 2012 | 476 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 2055 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2012 | 604 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1021 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 1245 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2016 | 11965 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2013 | 691 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 3890 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2014 | 1996 | 0.020 |
Why?
|
| Thrombosis | 1 | 2013 | 781 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2015 | 1471 | 0.020 |
Why?
|
| Cytokines | 1 | 2015 | 2809 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 4233 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 2291 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 4971 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 7548 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 6311 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 5395 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 1586 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 6295 | 0.020 |
Why?
|
| Public Health Nursing | 1 | 2003 | 1 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 3022 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2012 | 5637 | 0.010 |
Why?
|
| Cultural Characteristics | 1 | 2003 | 70 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5539 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2004 | 492 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 4821 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2003 | 597 | 0.010 |
Why?
|
| beta Catenin | 1 | 2004 | 688 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2004 | 1064 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2016 | 16273 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2004 | 1459 | 0.010 |
Why?
|
| Mutation | 1 | 2018 | 15179 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2004 | 1555 | 0.010 |
Why?
|
| Animals | 2 | 2018 | 59536 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 8873 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 34495 | 0.000 |
Why?
|